June 17, 2025
Enzo Biochem Reports Third Quarter Fiscal Year 2025 Results
FARMINGDALE, N.Y., June 16, 2025 (GLOBE NEWSWIRE) — Enzo Biochem, Inc. (OTCQX: ENZB) (“Enzo” or the “Company”) today announced financial…
Pharmaceuticals, Biotechnology and Life Sciences
FARMINGDALE, N.Y., June 16, 2025 (GLOBE NEWSWIRE) — Enzo Biochem, Inc. (OTCQX: ENZB) (“Enzo” or the “Company”) today announced financial…
ROCKVILLE, Md. and SUZHOU, China, June 15, 2025 (GLOBE NEWSWIRE) — Ascentage Pharma (NASDAQ: AAPG; HKEX: 6855), a global biopharmaceutical…
EAACI: Dupixent demonstrated superiority over Xolair (omalizumab) in chronic rhinosinusitis with nasal polyps in patients with coexisting asthma in first-ever…
New late-breaking data at EAACI showed Dupixent outperformed Xolair across all primary and secondary efficacy endpoints of CRSwNP and in…
With up to three years of follow-up, a single dose of lonvo-z led to a 98% mean reduction in monthly…
– Pharmacology modeling data presented at the European Academy of Allergy & Clinical Immunology (EAACI) Congress describe mechanistic insights for…
Media ReleaseCOPENHAGEN, Denmark; June 15, 2025 Results from the EPCORE® NHL-2 trial show investigational treatment with epcoritamab in combination with…
Results from the Phase 2 RedirecTT-1 study demonstrate deep responses with 78.9 percent overall response rate through dual targeting of…
After a thorough clinical review, the benefit-risk for the use of Elevidys in non-ambulatory patients with Duchenne has been re-assessed,…
77% of patients (150 mg Q4W) treated with barzolvolimab who had angioedema at baseline were angioedema free at Week 52Data…